[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484 254 6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 67, "title": "Co-Founder, Chief Scientist Officer, Chairman & Interim CEO", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 825000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 61, "title": "Chief Business Officer & Co-CEO of Hope Therapeutics", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 338000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael S. Abrams", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 63, "title": "Chief Manufacturing & Technology Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 77, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.02, "open": 3.07, "dayLow": 3.0, "dayHigh": 3.38, "regularMarketPreviousClose": 3.02, "regularMarketOpen": 3.07, "regularMarketDayLow": 3.0, "regularMarketDayHigh": 3.38, "payoutRatio": 0.0, "beta": 1.744, "forwardPE": -2.440945, "volume": 1089346, "regularMarketVolume": 1088424, "averageVolume": 464853, "averageVolume10days": 421650, "averageDailyVolume10Day": 421650, "bid": 3.02, "ask": 3.19, "bidSize": 3, "askSize": 3, "marketCap": 73686688, "fiftyTwoWeekLow": 1.12, "fiftyTwoWeekHigh": 6.01, "allTimeHigh": 769.9, "allTimeLow": 1.1, "fiftyDayAverage": 3.0146, "twoHundredDayAverage": 2.724095, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 68029736, "profitMargins": 0.0, "floatShares": 13611085, "sharesOutstanding": 23769901, "sharesShort": 915877, "sharesShortPriorMonth": 679818, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0385, "heldPercentInsiders": 0.11553001, "heldPercentInstitutions": 0.25752002, "shortRatio": 2.2, "shortPercentOfFloat": 0.0417, "impliedSharesOutstanding": 24315440, "bookValue": -1.829, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -33793000, "trailingEps": -2.21, "forwardEps": -1.27, "lastSplitFactor": "1:10", "lastSplitDate": 1712016000, "enterpriseToEbitda": -4.815, "52WeekChange": 1.3484848, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 3.1, "targetHighPrice": 47.0, "targetLowPrice": 25.0, "targetMeanPrice": 36.5, "targetMedianPrice": 37.0, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 2910000, "totalCashPerShare": 0.148, "ebitda": -14127500, "totalDebt": 9854000, "quickRatio": 0.072, "currentRatio": 0.113, "returnOnAssets": -1.74879, "freeCashflow": 8726875, "operatingCashflow": -11912000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "NRXP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1761955099, "regularMarketTime": 1761940801, "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "exchange": "NCM", "messageBoardId": "finmb_319388181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.649, "regularMarketPrice": 3.1, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1512397800000, "postMarketChangePercent": -0.967741, "postMarketPrice": 3.07, "postMarketChange": -0.029999971, "regularMarketChange": 0.0799999, "regularMarketDayRange": "3.0 - 3.38", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 464853, "fiftyTwoWeekLowChange": 1.9799999, "fiftyTwoWeekLowChangePercent": 1.7678571, "fiftyTwoWeekRange": "1.12 - 6.01", "fiftyTwoWeekHighChange": -2.9100003, "fiftyTwoWeekHighChangePercent": -0.48419306, "fiftyTwoWeekChangePercent": 134.84848, "earningsTimestamp": 1755520200, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "earningsCallTimestampStart": 1755691200, "earningsCallTimestampEnd": 1755691200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.21, "epsForward": -1.27, "epsCurrentYear": -0.27333, "priceEpsCurrentYear": -11.341601, "fiftyDayAverageChange": 0.085399866, "fiftyDayAverageChangePercent": 0.028328756, "twoHundredDayAverageChange": 0.3759048, "twoHundredDayAverageChangePercent": 0.13799253, "priceToBook": -1.6949152, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroRx, Inc.", "nameChangeDate": "2025-10-31", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "NRx Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]